Contact Us
Drug Search Results
More Filters [+]

Rifapentine

Alternative Names: rifapentine, m000473, priftin
Latest Update: 2025-01-21
Latest Update Note: Clinical Trial Update

Product Description

Rifapentine is a rifamycin antibiotic with antimycobacterial activity. Rifapentine is generally more active against Mycobacterium tuberculosis than rifampicin (rifampin), although strains resistant to rifampicin are usually cross-resistant to rifapentine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9806107/)

Mechanisms of Action: RNA polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Chile | China | Hong Kong | Indonesia | Peru | Philippines | Russia | Singapore | South Africa | Taiwan | United Kingdom | United States | Uruguay

Approved Indications: Traumatic Brain Injury | Latent Tuberculosis | Tuberculosis | Tuberculosis, Pulmonary

Known Adverse Events: Back Pain | Headache | Pain Unspecified | Anemia | Lymphopenia | Thrombocytosis | Neutropenia | Latent Tuberculosis | Tuberculosis | Tuberculosis, Pulmonary | Arthralgia | Hemoptysis | Anorexia

Company: Woolcock Institute of Medical Research
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rifapentine

Countries in Clinic: South Africa

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Latent Tuberculosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT03730181

P2

Active, not recruiting

Latent Tuberculosis

2024-05-15

Recent News Events

Date

Type

Title

12/19/2024

News Article

 Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

10/22/2024

News Article

 Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

10/16/2024

News Article

 ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024

03/28/2024

News Article

 FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions